Logo-bi
Original Research
Khalil EL Khatabi ORCID, Ilham Aanouz, Marwa Alaqarbeh, Mohammed Aziz Ajana, Tahar Lakhlifi, Mohammed Bouachrine* ORCID
BioImpacts. 2022;12(2): 107-113. doi: 10.34172/bi.2021.22143
PMCID: PMC8905587     PMID: 35411302     Scopus ID: 85127183196    
Molecular docking was performed to explore the binding affinity of the 12 selected molecules in the target enzyme and then evaluated for in silico ADMET properties. The best hits were subjected to molecular dynamics simulation.
Letter to the Editor COVID-19
Yosef Masoudi-Sobhanzadeh* ORCID
Bioimpacts. 2020;10(3): 205-206. doi: 10.34172/bi.2020.25
PMCID: PMC7416005     PMID: 32793443     Scopus ID: 85089710496    
This letter aims to introduce drug repurposing methods and the existing challenges to detect candidate drugs which may be helpful in controlling COVID-19.
Editorial COVID-19
Jaleh Barar* ORCID
Bioimpacts. 2020;10(3): 137-138. doi: 10.34172/bi.2020.16
PMCID: PMC7416010     PMID: 32793434     Scopus ID: 85089709760    
The vast knowledge about the pathways that regulate the virus entry and molecular signaling of the pathogenesis of coronavirus are the key factor for the development of de novo nanoscaled diagnostic/therapeutic strategies.
Prospective Highlights COVID-19
Morteza Mahmoudi* ORCID, Loraleigh Keashly
Bioimpacts. 2020;10(3): 139-140. doi: 10.34172/bi.2020.17
PMCID: PMC7416009     PMID: 32793435     Scopus ID: 85089707838    
In this perspective piece we will explore the potential facilitative influence of COVID-19 and specifically responses to it, on bullying behaviors in academic and research environments.
Perspective COVID-19
Mohammad Hossein Ahmadi* ORCID
BioImpacts. 2021;11(3): 169-172. doi: 10.34172/bi.2021.12
PMCID: PMC8314034     PMID: 34336604     Scopus ID: 85109083920    
A schematic representation of the application of viral interference phenomenon in prophylaxis of COVID-19. The viral interference is a competition phenomenon by which a primary virus infecting a cell prohibits the infection of the same cell by another (secondary) virus.
Original Research COVID-19
Khalil Ansarin ORCID, Ramin Tolouian, Mohammadreza Ardalan* ORCID, Ali Taghizadieh, Mojtaba Varshochi, Soheil Teimouri, Tahere Vaezi, Hamed Valizadeh, Parviz Saleh, Saeid Safiri ORCID, Kenneth R. Chapman ORCID
Bioimpacts. 2020;10(4): 209-215. doi: 10.34172/bi.2020.27
PMCID: PMC7502909     PMID: 32983936     Scopus ID: 85092050012    
Based on a randomized clinical trial, bromhexine is proposed as a potential therapeutic option in COVID-19. A total of 78 patients with similar demographic and disease characteristics were treated with results showing a significant reduction in ICU admissions.
Perspective
Sajad Khiali ORCID, Afra Rezagholizadeh ORCID, Taher Entezari-Maleki* ORCID
BioImpacts. 2022;12(3): 291-292. doi: 10.34172/bi.2022.23266
PMCID: PMC9124879     PMID: 35677665     Scopus ID: 85132071249    
In the present perspective piece, three possible mechanisms of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an oncogenic virus in the lung have been discussed.
Letter to the Editor
Ata Mahmoodpoor ORCID, Ali Shamekh, Sarvin Sanaie* ORCID
BioImpacts. 2022;12(2): 175-177. doi: 10.34172/bi.2021.42
PMCID: PMC8905593     PMID: 35411301     Scopus ID: 85127196118    
Original Research
Yang Han ORCID, Zhilong Jia* ORCID, Jinlong Shi, Weidong Wang*, Kunlun He*
BioImpacts. 2022;12(2): 139-146. doi: 10.34172/bi.2021.23378
PMCID: PMC8905590     PMID: 35411293     Scopus ID: 85127131228    
The enrichment of several other pathogens, immunomodulatory probiotics (lactic acid or butyrate producers), and TMV in the COVID-19 group suggests a complex and active lung microbiota disorder.
Editorial COVID-19
Alireza Farnam* ORCID
BioImpacts. 2021;11(3): 165-167. doi: 10.34172/bi.2021.30
PMCID: PMC8314038     PMID: 34336603     Scopus ID: 85109077429    
Alireza Farnam is a Professor of Psychiatry at Tabriz University of Medical Sciences, with main expertise in Personology, Psychanalysis, Neurosciences and Clinical psychiatry research. His recent researches fo­cus on neuro-psychiatry, neuro-philosophy and self-awareness.
Original Research COVID-19
Mohammad Mostafa Pourseif ORCID, Sepideh Parvizpour, Behzad Jafari, Jaber Dehghani ORCID, Behrouz Naghili, Yadollah Omidi* ORCID
BioImpacts. 2021;11(1): 65-84. doi: 10.34172/bi.2021.11
PMCID: PMC7803919     PMID: 33469510     Scopus ID: 85099197264    
Immunodominant T-cell epitopes of SARS-CoV-2 spike protein with the highest population coverage were predicted by analyzing peptide binders and consensus rank (CR) score. Multi-method B-cell epitope prediction approach was used to find B-cell immunodominant regions of spike protein. Upon the high immune-potent regions of the antigen(s), self-amplifying mRNA and peptide-based vaccines were designed.

Original Research
Yosef Masoudi-Sobhanzadeh* ORCID, Hosein Esmaeili ORCID, Ali Masoudi-Nejad* ORCID
BioImpacts. 2022;12(4): 315-324. doi: 10.34172/bi.2021.40
PMCID: PMC9376160     PMID: 35975205     Scopus ID: 85137344477    
The required data, including proteins and enzymes, are divided into smaller parts and are mined using the existing processors. The proposed method computes the alignment similarity between the existing proteins and SARS-CoV-2’s proteins based on the proposed fuzzy logic system.
Review
Luigi X Cubeddu* ORCID, Daisy de la Rosa, Michele Ameruoso
Bioimpacts. 2022;12(1): 9-20. doi: 10.34172/bi.2021.23630
PMCID: PMC8783084     PMID: 35087712     Scopus ID: 85127123894    
A combination of old age, comorbidities, increased cytokine levels and proarrhythmic drug therapies canexplain the increased arrhythmic events reported in severe COVID-19 disease.
Review
Maryam Sayahinouri ORCID, Sahar Mashayekhi Firouz ORCID, Amin Ebrahimi Sadrabadi ORCID, Mina Masoudnia ORCID, Mahnaz Abdolahi ORCID, Fatemeh Jafarzadeh ORCID, Meshkat Nouripour ORCID, Sana Mirzazadeh ORCID, Nazanin Zangeneh ORCID, Arsalan Jalili* ORCID, Nasser Aghdami ORCID
Bioimpacts. 2023;13(2): 159-179. doi: 10.34172/bi.2023.23839
PMCID: PMC10182441     PMID: 37193075     Scopus ID: 85152105286    
In COVID-19 infection, the various functions of immune cells lead to defense or failure against the virus. Cell therapy is of great importance as a new treatment for COVID-19 infection. Therefore, in this review, we have dealt with the function of immune cells against the SARS-Cov-2 virus and new treatment methods for this disease with the help of different cell types
Letter to the Editor
Aleksandr L. Urakov* ORCID, Natalya A. Urakova, Ilnur I. Yagudin, Milena D. Svetova, Darya O. Suntsova
BioImpacts. 2022;12(4): 393-394. doi: 10.34172/bi.2022.23877
PMCID: PMC9376158     PMID: 35975207     Scopus ID: 85138077187    
The purpose of this letter was to present a model for evaluating the biological activity of drugs, which can become a new vector for the development of effective ways to increase blood oxygenation across pulmonary and save the lives of patients with severe atypical pneumonia complicated by respiratory obstruction in COVID-19.
Spotlight
Danial Mehranfard ORCID, Robert C. Speth* ORCID
BioImpacts. 2022;12(2): 171-174. doi: 10.34172/bi.2022.23980
PMCID: PMC8905591     PMID: 35411295     Scopus ID: 85127141535    
This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.
Editorial
Azam Safary ORCID, Mostafa Akbarzadeh-Khiavi ORCID, Jaleh Barar ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2023;13(4): 269-273. doi: 10.34172/bi.2023.27494
PMCID: PMC10460773     PMID: 37645029     Scopus ID: 85168085723    
Professor Yadollah Omidi has a Ph.D. degree in Pharmaceutical Sciences (2003, Cardiff University, UK). He is currently working as a full professorat Nova Southeastern University College of Pharmacy, Florida. He has consecutively been listedamong top 1% highly cited scientists worldwide by WoS-ESI.
Review
Elina Armani Khatibi ORCID, Nastaran Farshbaf Moghimi, Elaheh Rahimpour* ORCID
Bioimpacts. 2024;14(6): 29968. doi: 10.34172/bi.2024.29968
PMCID: PMC11530968     PMID: 39493896     Scopus ID: 85209246738    


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge